Replies to post #1402 on Vascular Biogenics Ltd (VBLT)

[staccani]

When I look at the 'Durable disease and Control slides' presented at ASCO 2016 (June), 9 patients out of 15 evaluable patients at the time had been less than 100 days on trial (closer to 50 days than to 100 days), so they would be around 14 months or less on trial as of June 17 when the LT survival data was disclosed. This might mean that half of the patients we do not see in the September 17 presentation had been on trial for less than 15.7M as of June 2017 (not appearing in the presentation) and yet may still be alive, hence the final mOS maybe has not been reached yet, so 15.7M in this case would be the minimum mOS. But this is just an assumption.